BeiGene's BTK-targeted protein degrading agent is accepted for clinical application in China

ArticleMedicine Guanlan

On October 26, the latest announcement by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration showed that BeiGene submitted a clinical trial application for BGB-16673 film-coated tablets and was accepted

Screenshot source: CDE official website

The principle of protein degradation therapy is: link specific proteins with "tag" ubiquitin ligase, label these proteins with "recyclable", and transport them to the proteasome system for degradation, so as to treat diseases Purpose

According to public information released by BeiGene earlier, based on protein degradation technology, the company has developed a platform technology called CDAC, which can target difficult-to-medicine targets or mutant proteins

At present, BeiGene has established a number of CDAC product pipelines, and BGB-16673 is one of the fastest-growing products

▲CDAC platform of BeiGene (Source: BeiGene Public PPT)

Public information shows that BGB-16673 is a protein degradation agent targeting Bruton's tyrosine kinase (BTK)

At the same time, the industry is also committed to the development of a new generation of BTK targeted drugs, of which BTK targeted protein degradation agents are currently one of the important research and development directions in this field

Preclinical models show that BGB-16673 can overcome C481S resistance and is expected to break through the patient's resistance to Zebutinib and other BTK inhibitors

Reference materials:

[1] Center for Drug Evaluation of China National Medical Products Administration.

[2] BeiGene PPT.